Cargando…

24-h Efficacy of Glaucoma Treatment Options

Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstas, Anastasios G. P., Quaranta, Luciano, Bozkurt, Banu, Katsanos, Andreas, Garcia-Feijoo, Julian, Rossetti, Luca, Shaarawy, Tarek, Pfeiffer, Norbert, Miglior, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846688/
https://www.ncbi.nlm.nih.gov/pubmed/26909513
http://dx.doi.org/10.1007/s12325-016-0302-0
_version_ 1782429081050021888
author Konstas, Anastasios G. P.
Quaranta, Luciano
Bozkurt, Banu
Katsanos, Andreas
Garcia-Feijoo, Julian
Rossetti, Luca
Shaarawy, Tarek
Pfeiffer, Norbert
Miglior, Stefano
author_facet Konstas, Anastasios G. P.
Quaranta, Luciano
Bozkurt, Banu
Katsanos, Andreas
Garcia-Feijoo, Julian
Rossetti, Luca
Shaarawy, Tarek
Pfeiffer, Norbert
Miglior, Stefano
author_sort Konstas, Anastasios G. P.
collection PubMed
description Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0302-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4846688
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-48466882016-05-21 24-h Efficacy of Glaucoma Treatment Options Konstas, Anastasios G. P. Quaranta, Luciano Bozkurt, Banu Katsanos, Andreas Garcia-Feijoo, Julian Rossetti, Luca Shaarawy, Tarek Pfeiffer, Norbert Miglior, Stefano Adv Ther Review Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0302-0) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-02-24 2016 /pmc/articles/PMC4846688/ /pubmed/26909513 http://dx.doi.org/10.1007/s12325-016-0302-0 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Konstas, Anastasios G. P.
Quaranta, Luciano
Bozkurt, Banu
Katsanos, Andreas
Garcia-Feijoo, Julian
Rossetti, Luca
Shaarawy, Tarek
Pfeiffer, Norbert
Miglior, Stefano
24-h Efficacy of Glaucoma Treatment Options
title 24-h Efficacy of Glaucoma Treatment Options
title_full 24-h Efficacy of Glaucoma Treatment Options
title_fullStr 24-h Efficacy of Glaucoma Treatment Options
title_full_unstemmed 24-h Efficacy of Glaucoma Treatment Options
title_short 24-h Efficacy of Glaucoma Treatment Options
title_sort 24-h efficacy of glaucoma treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846688/
https://www.ncbi.nlm.nih.gov/pubmed/26909513
http://dx.doi.org/10.1007/s12325-016-0302-0
work_keys_str_mv AT konstasanastasiosgp 24hefficacyofglaucomatreatmentoptions
AT quarantaluciano 24hefficacyofglaucomatreatmentoptions
AT bozkurtbanu 24hefficacyofglaucomatreatmentoptions
AT katsanosandreas 24hefficacyofglaucomatreatmentoptions
AT garciafeijoojulian 24hefficacyofglaucomatreatmentoptions
AT rossettiluca 24hefficacyofglaucomatreatmentoptions
AT shaarawytarek 24hefficacyofglaucomatreatmentoptions
AT pfeiffernorbert 24hefficacyofglaucomatreatmentoptions
AT migliorstefano 24hefficacyofglaucomatreatmentoptions